Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Citi
AstraZeneca
Moodys
Chinese Patent Office
Harvard Business School
Accenture
McKesson
Boehringer Ingelheim

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,375,478

« Back to Dashboard

Which drugs does patent 9,375,478 protect, and when does it expire?

Patent 9,375,478 protects VASOSTRICT and is included in one NDA.
Summary for Patent: 9,375,478
Title:Vasopressin formulations for use in treatment of hypotension
Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
Inventor(s): Kenney; Matthew (New Haven, MI), Kannan; Vinayagam (Rochester, MI), Vandse; Sunil (Basking Ridge, NJ), Sanghvi; Suketu (Kendall Park, NJ)
Assignee: PAR PHARMACEUTICAL, INC. (Chestnut Ridge, NY)
Application Number:14/717,882
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,375,478
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,375,478

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Par Sterile Products VASOSTRICT vasopressin SOLUTION;IV (INFUSION) 204485-001 Apr 17, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES ➤ Try a Free Trial
Par Sterile Products VASOSTRICT vasopressin SOLUTION;IV (INFUSION) 204485-002 Dec 17, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,375,478

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,744,239 Vasopressin formulations for use in treatment of hypotension ➤ Try a Free Trial
9,687,526 Vasopressin formulations for use in treatment of hypotension ➤ Try a Free Trial
9,750,785 Vasopressin formulations for use in treatment of hypotension ➤ Try a Free Trial
9,744,209 Vasopressin formulations for use in treatment of hypotension ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
US Department of Justice
Federal Trade Commission
Healthtrust
Medtronic
Express Scripts
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.